Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > EBCC manifesto urges action to overcome disparities in metastatic breast cancer
  • News

EBCC manifesto urges action to overcome disparities in metastatic breast cancer

  • 5 April 2024
  • Janet Fricker
EBCC manifesto urges action to overcome disparities in metastatic breast cancer
Total
0
Shares
0
0
0
0
0

All patients with metastatic breast cancer should have equal access to the best treatments and outcomes regardless of where they live in Europe. The EBCC14 manifesto, agreed at the 14th European Breast Cancer Conference (EBCC) on March 22 in Milan, considered recommendations to address metastatic breast cancer issues around stigma, registries and real-world data, multidisciplinary care, clinical research, quality indicators, and returning to the workplace.

“There are disparities not only across Europe but within countries regarding access to multidisciplinary quality care, information, and innovative new treatments. In order to bridge the gap between patients who get the best care and those who do not we have been working on this manifesto for the implementation of effective health policies for patients with metastatic breast cancer,” said Fiorita Poulakaki, co-chair of the session, from the Athens Medical Centre, Greece.

All too often, women with metastatic breast cancer can feel that they have been abandoned and are not getting the attention they deserve, Michail Ignatiadis, chair of the EBCC meeting from Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels, tells Cancerworld. “This needs to change. Due to recent advances in medicine many of these women will live for years. They have the right to get the best in terms of diagnosis, management, and being able to live a normal life, regardless of whether their life expectancy is short, medium, or long,” he says.

At each biennial EBCC Meeting, the EBCC Manifesto identifies topics that need to be addressed, taking into account differences across European countries. The seven recommendations presented in the ‘Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe’ manifesto were devised by the EBCC Scientific Committee, with the final text taking into consideration audience comments from the session. “EBCC” is a unique meeting in the sense that it is the only multidisciplinary meeting in Europe for breast cancer where medical oncologists, surgeons, radiotherapists, pathologists, translational researchers, policy makers, patients and patient advocates all come together to discuss current data in the treatment of breast cancer,” explains Ignatiadis. “We believe that the best care is given to patients by taking a multidisciplinary approach.”

The manifesto is aligned with other initiatives aiming to change the collective mentality towards metastatic breast cancer, including the ABC Global Alliance and the Lancet Breast Cancer Commission. The plan is for the final article to be submitted to the European Journal of Cancer for peer review.

The seven recommendations outlined in the manifesto were:

1. Increase the visibility of metastatic breast cancer to society and facilitate involvement of people with metastatic breast cancer in trials, the workplace, and everyday life as much as they want and are able.

Fiorita Poulakaki made the case for policy makers to acknowledge that people living with metastatic breast cancer should have the same opportunities and rights as the rest of the population. “People with metastatic breast cancer are undercounted, undervalued, and underrepresented. We want these people to be counted and seen and treated properly,” she said. “We must make sure they continue their important contribution to society, family, arts and science.” Important issues needing to be addressed, she added, include introduction of laws to protect people’s right to work and receive the best possible care regardless of prognosis, in order to enhance survival outcomes and quality of life.

2. Implement a National Cancer Registry in every European country that records stage at diagnosis and relapse, and share the data with the International Agency for Research on Cancer (IARC), to understand how many people are living with metastatic breast cancer.

Not all countries have a registry for early breast cancer let alone metastatic breast cancer, said Frederieke Van Duijnhoven (Netherlands Cancer Institute, Amsterdam). “If we want to solve the problem, we have to know everything we can about its size and characteristics,” she explained, adding that national registries need to be aligned with international data. The next hurdle, she said, was getting data across borders. “We implore policy makers to somehow waive the data policy for this type of data so that we can ensure reliable data throughout Europe that we can use to compare, identify and solve the problem of metastatic breast cancer health care.”

3. Harmonise, monitor, and use routinely collected real-world and registry data (including but not limited to details of biomarker/ genetic testing, treatment, and quality of life) to support reimbursement policies and improve access to treatment, trials and services and to evaluate outcomes.

Valesca Retel (Netherlands Cancer Institute) defined real-world data as: clinical data including information on reimbursement, patient reported outcome measures, quality of life and genetic testing. Genetic testing information, she added, was especially important for patients with metastatic breast cancer to access targeted treatments.

An audience comment underlined the need to adopt a more ‘holistic approach’, by providing real-world information not just on diagnosis and treatment, but also quality of life and psychological effects.

4. Ensure all patients with metastatic breast cancer in Europe have access to high-quality multidisciplinary information and care (imaging, molecular biology, pathology, radiation, systemic therapy, surgery, side-effect management, palliative care, trials, etc).

Icro Meattini (University of Florence) said that, for optimal treatment, patients need to have optimal access to high-quality multidisciplinary information and care.

5. Design a mechanism to fund Europe-wide pragmatic optimisation trials to address questions of public interest.

Etienne Brain (Institut Curie Saint-Cloud, France) said that there is high discrepancy between the endpoints that are important to patients and treating physicians compared to those used by trialists. “One of the most important aspects of these pragmatic questions is how we select better what is essential to collect,” he said.

Gabe Sonke (Netherlands Cancer Institute) commented that, while trials exploring drug optimisation are not usually supported by industry, it should be possible for academic institutions to fund them. “By giving less intensive treatments we give less expensive treatments. We have to design mechanisms to get the savings into the trial system,” he said. Other comments covered the need to create specific pathways allowing patient organisations to participate in proposing the questions.

6. Ensure implementation of newly established quality indicators across Europe

Orit Kaidar-Person (Sheba Medical Center, Ramat Gan, Israel) said that the ABC Global Alliance now provides quality indicators for metastatic breast cancer. “These can help us evaluate how we are doing in clinic, and how we improve if we implement the registries and real-world data. We can make sure that we are giving our patients the best of care.”

A proposal was made that achieving quality indicators should be linked to funding and accreditation of metastatic breast units.

7. Consider developing and introducing a tool to rate the importance of interventions beyond anticancer drugs (similar to the ESMO Magnitude of Clinical Benefit Scale for drugs).

Michail Ignatiadis argued that the ESMO Magnitude of Clinical Benefit Scale offers a great tool to help stakeholders make important decisions. “But drugs are not the end of the story. We need to create this kind of scale for the whole patient journey, including screening, diagnosis, treatment, and supportive care.”

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • access
  • discrimination
  • genomic testing
  • high-quality care
  • metastatic breast cancer
  • multidisciplinary team
  • pragmatic trials
  • quality indicators
  • registries and real-world data
  • stigma
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Articles
  • Policy

Por fin! A cancer prevention code for Latin America and the Caribbean

  • 3 April 2024
  • Myriam Vidal Valero
View Post
Next Article
Secondhand cancer and chemotherapy
  • News

Secondhand smoke reduces cisplatin impact on head & neck tumour cells

  • 5 April 2024
  • Janet Fricker
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Yeva Margaryan
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Yeva Margaryan
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.